Revvity, Inc. (RVTY) Balance Sheet

The reduction in debt coincides with the completion of the divestiture of the legacy industrial businesses, which appears to have generated proceeds used to retire borrowings rather than fund new acquisitions. Total assets have contracted from $13.4B to $11.5B over the same period, largely reflecting the exit of lower-margin operations, so the leverage improvement is partly a function of a smaller asset base. Investors should monitor whether further deleveraging is sustainable given that the current ratio has compressed from 3.6 to 1.7 over 2025, which may indicate a shift in the composition of liquid assets toward cash deployment.

Debt declined from $3.5B at year-end 2025 to $2.8B by 2026Q3, which may reflect scheduled repayments or proceeds from asset sales rather than a discretionary balance sheet strategy. The leverage profile is conservative for a company of this scale, which supports financial flexibility, though the absolute debt load still represents a significant claim on operating cash flow. Analysts should verify the maturity schedule in the filings, as the debt structure rather than the headline ratio will determine interest burden and rollover risk.

The concentration of value in goodwill and intangibles reflects the premium paid for acquisitions such as BioLegend, and it creates impairment exposure if the growth assumptions underlying those deals fail to materialize. Net PP&E has declined from $676M to $598M over the past six quarters, consistent with a capital-light model and low reinvestment intensity. The quality of the asset base therefore rests heavily on the durability of acquired intangibles rather than on tangible productive capacity.

Retained earnings growth indicates that accumulated profits are being retained after dividends and modest buybacks, which supports the quality of book equity. The absence of material share issuance in the reported period implies limited dilution pressure, although stock-based compensation may still erode per-share value over time. Investors should separately examine share count trends in the filings to confirm that buyback activity is offsetting dilution.

The decline in cash coincides with acquisition outflows and debt repayment, which may be a deliberate use of excess liquidity but also reduces the cushion against operating shocks. A current ratio of 1.7 remains adequate for a company with recurring consumables revenue and positive operating cash flow. Investors should confirm that the cash balance is sufficient for working capital needs given tariff-related supply chain uncertainty.